Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KL1333 in Healthy Male Volunteers
NCT03056209Phase 1Completed
- Sponsor
- Yungjin Pharm. Co., Ltd.
- Start
- Jun 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of napazimone in mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS) (7 arms), sponsored by Yungjin Pharm. Co., Ltd. Primary endpoint: Number of reported adverse events. Started Jun 2017; status: completed.
02
Drugs
napazimone
03
Conditions
mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS)
Beyond the preview
Go deeper on NCT03056209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056209.